Innovating Works

H2020

Cerrada
HORIZON-JU-IHI-2022-03-05
HORIZON-JU-IHI-2022-03-05: Digital health technologies for the prevention and personalised management of mental disorders and their long-term health consequences
ExpectedOutcome:R&I actions (projects) to be supported under this topic must contribute to all of the following outcomes:
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 15-03-2023.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Hace más de 21 mes(es) del cierre y aún no tenemos información sobre los proyectos financiados, no parece que se vaya a publicar esta información.
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio..
Esta ayuda financia Proyectos:

ExpectedOutcome:R&I actions (projects) to be supported under this topic must contribute to all of the following outcomes:

Robust evidence on the feasibility, acceptability, adherence, and personal satisfaction with digital health technologies (DHT) in people with mental disorders. People with mental disorders and their families/caregivers should be included in evidence generation. This includes pathways to maximise motivation and engagement with DHT of all relevant end-users and healthcare actors. This includes patient-centric selection of potential application features, measurement technologies and digital endpoints. Proper attention should be given to the issues of vulnerability, stigma and difficulties related to limited digital/eHealth literacy. Consideration should be given to ethical, cultural, gender and age-specific (e.g. adolescents’) needs and preferences to ensure continued use of the DHT.A flexible, interoperable, and reusable digital platform that can be used across numerous conditions and scenarios (various mental disorders, comorbidities, long-term health consequences and other disease areas) to collect, analyse and integrate diverse multimodal c... ver más

ExpectedOutcome:R&I actions (projects) to be supported under this topic must contribute to all of the following outcomes:

Robust evidence on the feasibility, acceptability, adherence, and personal satisfaction with digital health technologies (DHT) in people with mental disorders. People with mental disorders and their families/caregivers should be included in evidence generation. This includes pathways to maximise motivation and engagement with DHT of all relevant end-users and healthcare actors. This includes patient-centric selection of potential application features, measurement technologies and digital endpoints. Proper attention should be given to the issues of vulnerability, stigma and difficulties related to limited digital/eHealth literacy. Consideration should be given to ethical, cultural, gender and age-specific (e.g. adolescents’) needs and preferences to ensure continued use of the DHT.A flexible, interoperable, and reusable digital platform that can be used across numerous conditions and scenarios (various mental disorders, comorbidities, long-term health consequences and other disease areas) to collect, analyse and integrate diverse multimodal clinical and patient data, including patient reported outcome measures (PROMs) and patient reported experience measures (PREMs), with an emphasis on those generated by DHT. Variability across countries should be addressed, as digital infrastructures and the availability of digital tools may differ. Mapping of the specific links between digital infrastructures and types of digital health technology (e.g. concepts, data types, standards, technological approaches) should be included. Consideration must be given to ethical, social, and legal aspects and to the FAIR (findable, accessible, interoperable, reusable) principles.Effective and agreed guidelines for the development and implementation of DHT in clinical research and as a part of everyday health and care, enabling the development of more patient-centric treatments, optimised health and care interventions and better disease prevention. Evidence from quantitative studies on potential favourable/unfavourable effects of the technologies on care, and on their impact on changing clinical research and clinical trials should be included. Relevant organisational and work processes, policy and regulatory aspects should be addressed to foster the sustained integration of DHT in real world practice.Robust knowledge for better understanding of mental disorders, their change over time and how all this relates to clinical outcomes including the remission, relapse, and recurrence of the conditions, long-term health conditions and mortality and/or surrogate outcome measures when relevant. Socioeconomic outcomes and family/caregiver burden should be addressed. Better insights into other aspects like patient adherence to therapy and adverse drug reactions should be gained.A robust body of data to enable the development of digital tools that optimise the engagement of people with mental disorders, caregivers and other relevant actors (healthcare professionals, social workers etc.) adapted to the needs of the patient population and age-specific needs, tackling the issues of stigma, vulnerability, lack of treatment seeking and overall poor adherence to treatment (including lifestyle related). Consideration should be given to providing intuitive equipment and user interfaces and easy troubleshooting.Enhanced and more reliable tools and methods (e.g. analytical tools and algorithms) able to provide (near) real time feedback on the DHT, including on the usability, efficacy/effectiveness, and long-term safety. Together, these enable healthcare professionals and providers to make more inclusive and efficient patient-centred decisions in collaboration with the people with mental disorders and their families.Robust evidence of how DHT may influence the treatment or behaviour of people with mental disorders. The inclusion of schools/social workers/psychologists in evidence generation should be considered where relevant.
Scope:Mental health disorders represent an area of severe unmet public health need. This has been further negatively impacted by the COVID-19 pandemic, with a substantial increase in the number and severity of people affected for example by anxiety and depression1, which places substantial pressures on already strained mental health care systems. People with mental disorders have a reduced life expectancy compared to the general population, and this is linked to a greater risk of developing a range of chronic physical conditions2. The long-standing separation of psychiatry from other branches of medicine and the lack of specific training on this issue further contribute to the poor attention dedicated to management of comorbidities of mental health disorders.

Digital health technologies (DHT) applied via electronic devices such as wearable sensors, implanted equipment, and handheld instruments and smartphones have already shown significant promise for the prevention and disease management of chronic conditions (e.g. cardiovascular disease, diabetes, obesity). DHT, by making it possible to virtually perform medical activities that have traditionally been conducted in person, also have the potential to decrease the pressure on healthcare systems and their personnel. Thus, DHT might have the potential to address some of the challenges in the prevention, prediction, monitoring and personalised management of mental disorders and their long-term health consequences, as well as to tackle some of the organisational issues in providing mental health care3.

The scope of this topic is to investigate how DHT might positively impact the healthcare pathway for people with mental disorders.

Applicants should demonstrate how DHT may enable:

better prevention and prediction of disorder onset or relapse;better disease management;tackling comorbidities;addressing long-term health consequences (such as cardiovascular disease or diabetes). The choice of the specific mental disorder should be justified based on unmet public health need, its impact on quality of life of people with mental disorders and their families/caregivers as well as the feasibility and preliminary evidence available on the use and value of DHT.

To contribute to breaking the silos between psychiatry and other medical branches and better address the impact of co-morbidities in people with mental disorders, applicants should consider relevant co-morbidity/ies where DHT data, learnings and technologies are already available and can be further developed/applied to mental disorders. Co-morbidities can significantly exacerbate mental health disorders, impacting quality of life and the development of long-term health consequences The choice of comorbidy/ies must therefore be justified accordingly.

Ways of decreasing the burden on caregivers and families should be considered, and applicants should actively engage these actors as well as the people with mental disorders in addressing critical issues and research questions, including about (sustained) engagement with DHT4. Consortia should propose ways to foster the future integration of digital and clinical mental healthcare, as well as how DHT might enhance the outcomes of interventions by social and healthcare professionals while decreasing the burden on the healthcare system. Applicants should adequately describe how they plan to measure such burden.

Resources and learnings from previous initiatives at European and national level (Innovative Medicines Initiative funded4 among others) should be taken into consideration.

Applicants should aim to deliver robust evidence on how DHT may be:

made easy to adopt and use in a sustained way for both people with mental disorders, their families/caregivers and health and care providers;effectively incorporated into clinical research and in clinician workflows. Early engagement with regulators should be sought to ensure the future acceptance and usability of the results for example through scientific advice, qualification advice or qualification opinion.

Applicants are expected to implement activities to achieve all expected outcomes.

Applicants are expected to consider allocating appropriate resources to explore synergies with other relevant initiatives and projects.

1 https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide

2 https://annals-general-psychiatry.biomedcentral.com/articles/10.1186/s12991-021-00374-y; https://www.nature.com/articles/s41569-020-00463-7

3 https://www.frontiersin.org/articles/10.3389/fdgth.2021.764079/full

4 https://www.imi.europa.eu/projects-results/project-factsheets?keywords=digital+technology&status=All&call=All&programmes=All&disease_areas=All&products=All&tools=All;

https://www.imi.europa.eu/projects-results/project-factsheets?keywords=radar+cns&status=All&call=All&programmes=All&disease_areas=All&products=All&tools=All


Expected Impact:The following impacts are expected:

Enhanced cross-sectoral collaboration between healthcare industries, academia and all other relevant actors of the healthcare ecosystem. This will be achieved keeping the people with mental disorders in the centre, outreaching to the social and educational system as relevant to foster sustained and patient-centric innovation in digital health technologies (DHT) for mental health care.Preparedness of the healthcare system for the implementation and integration of DHT with existing clinical care strategies thereby also decreasing the burden on staff.Prevention (primary and secondary, relapses, chronification, long-term health consequences), earlier and more precise diagnosis, more clinically effective interventions and monitoring, better patient adherence, and reduced hospitalisation (reduction in re-admission/period of hospitalisation).Demonstration of the added value of DHT for better management and care and improved experience of people with mental disorders and their families/caregivers, paving the way for a broader and sustained application of DHT in healthcare.More cost-effective care pathway management for people with mental disorders.Contribute to the upcoming ‘European Health Data Space’ by promoting better exchange of and access to different types of health data and data generated by DHT and other medical health technologies (using standards in data, technologies…).Knowledge and learnings on mental disorders’ long-term impact on physiology and physical health. This will contribute to the better overall health & well-being of the population, especially for people with mental health disorders.
ver menos

Temáticas Obligatorias del proyecto: Temática principal:

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: *Presupuesto para cada participante en el proyecto
Requisitos técnicos: ExpectedOutcome:R&I actions (projects) to be supported under this topic must contribute to all of the following outcomes: ExpectedOutcome:R&I actions (projects) to be supported under this topic must contribute to all of the following outcomes:
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Subcontracting costs.
Purchase costs.
Other cost categories.
Indirect costs.
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 4:. Es el primer paso para determinar si los componentes individuales funcionarán juntos como un sistema en un entorno de laboratorio. Es un sistema de baja fidelidad para demostrar la funcionalidad básica y se definen las predicciones de rendimiento asociadas en relación con el entorno operativo final. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
Para el presupuesto subvencionable la intensidad de la ayuda en formato fondo perdido podrá alcanzar como minimo un 100%.
The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations. The funding rate for RIA projects is 100 % of the eligible costs for all types of organizations.
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-JU-IHI-2022-03-single-stage Digital health technologies for the prevention and personalised management of mental disorders and their long-term health consequences ExpectedOutcome:R&I actions (projects) to be supported under this topic must contribute to all of the following outcomes: Robust eviden...
Sin info.
HORIZON-JU-IHI-2022-03-05 Digital health technologies for the prevention and personalised management of mental disorders and their long-term health consequences
en consorcio: ExpectedOutcome:R&I actions (projects) to be supported under this topic must contribute to all of the following outcomes: Robust eviden...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-03-04 Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases
en consorcio: ExpectedOutcome:Research and innovation (R&I) actions to be supported under this topic must work towards results that contribute to all...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-03-01 Screening platform and biomarkers for prediction and prevention of diseases of unmet public health need
en consorcio: ExpectedOutcome:R&I actions (projects) to be supported under this topic should aim to deliver results that contribute to all of the foll...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-03-03 Combining hospital interventional approaches to improve patient outcomes and increase hospital efficiency
en consorcio: ExpectedOutcome:Research and innovation (R&I) actions (projects) to be supported under this topic should aim to deliver results that con...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-03-02 Patient-generated evidence to improve outcomes, support decision making, and accelerate innovation
en consorcio: ExpectedOutcome:Research and innovation (R&I) actions (projects) to be supported under this topic should aim to deliver results that con...
Cerrada hace 1 año | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-01-03 Personalised oncology: innovative people centred, multi-modal therapies against cancer
en consorcio: ExpectedOutcome:R&I actions to be supported under this topic shall contribute to all the following outcomes: Platform, standards and re...
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-01-02 Next generation imaging and image-guided diagnosis and therapy for cancer
en consorcio: ExpectedOutcome:The proposals are expected to focus on image-based cancer diagnosis, prognosis, treatment planning and therapy. Project resu...
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-02-01 Cardiovascular diseases - improved prediction, prevention, diagnosis, and monitoring
en consorcio: ExpectedOutcome:The results of the selected project will provide the basis for better primary and secondary prevention of CVD. The goal is t...
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-02-02 Setting up a harmonised methodology to promote uptake of early feasibility studies for clinical and innovation excellence in the European Union
en consorcio: ExpectedOutcome:The research and innovation action to be supported under this topic is expected to deliver results including a methodology f...
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-01-01 An innovative decision-support system for improved care pathways for patients with neurodegenerative diseases and comorbidities
en consorcio: ExpectedOutcome:R&I actions to be supported under this topic shall contribute to the following outcomes: A (sustainable) re-usable, int...
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de
HORIZON-JU-IHI-2022-01-04 Access and integration of heterogeneous health data for improved healthcare in disease areas of high unmet public health need
en consorcio: ExpectedOutcome:Proposals under this topic should aim to deliver results that contribute to all of the following expected outcomes for a spe...
Cerrada hace 2 años | Próxima convocatoria prevista para el mes de